Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology

Hiroaki Kajiyama, Kiyosumi Shibata, Mika Mizuno, Tomokazu Umezu, Shiro Suzuki, Ryuichiro Sekiya, Kaoru Niimi, Hiroko Mitsui, Eiko Yamamoto, Michiyasu Kawai, Tetsuro Nagasaka, Fumitaka Kikkawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type. Methods: Five hundred and seventy-four patients with recurrent ovarian cancer with sufficient clinical information, including front-line chemotherapy, were analyzed. The pathologic slides were evaluated by central pathologic review. The patients were divided into two groups: group A (n=261), who underwent taxane plus platinum, and group B (n=313), who underwent conventional platinum-based chemotherapy without taxanes. Results: The median age was 54 years (range, 14 to 89 years). Group A had significantly better median OS (45.0 months vs. 30.3 months, p<0.001) and PRS (23.0 months vs. 13.0 months, p<0.001) compared to group B. The OS and PRS were similar between the groups in patients with clear cell or mucinous histology. In contrast, among patients with non-clear cell, non-mucinous histologies, the OS and PRS of group A were significantly better than those of group B (OS, p<0.001; PRS, p<0.001). Multivariable analyses revealed that, among patients with non-clear cell, non-mucinous histologies, chemotherapy including taxane and platinum was an independent predictor of favorable survival outcomes. Conversely, in patients with clear cell or mucinous histology, taxane-including platinum-based combination chemotherapy did not improve the OS and PRS compared to a conventional platinum-based regimen which did not include taxanes. Conclusion: Since the emergence of taxane plus platinum, the prognosis of patients with recurrent ovarian cancer has improved. However, we here demonstrate that this improvement is limited to patients with non-clear cell, non-mucinous histologies.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalJournal of Gynecologic Oncology
Volume25
Issue number1
DOIs
Publication statusPublished - 01-2014

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology'. Together they form a unique fingerprint.

  • Cite this

    Kajiyama, H., Shibata, K., Mizuno, M., Umezu, T., Suzuki, S., Sekiya, R., Niimi, K., Mitsui, H., Yamamoto, E., Kawai, M., Nagasaka, T., & Kikkawa, F. (2014). Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology. Journal of Gynecologic Oncology, 25(1), 43-50. https://doi.org/10.3802/jgo.2014.25.1.43